HRCM
CPRX

Hawk Ridge Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Hawk Ridge Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-654,859
Closed -$3.34M – 40
2019
Q1 		$3.34M Buy
+654,859
New +$1.93M 0.7% 36

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hawk Ridge Capital Management's CPRX Position: Q2 2019 in Review

Hawk Ridge Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2019, closing a stake of 654,859 shares — an estimated $3.34M sold.

Hawk Ridge Capital Management first reported a position in CPRX in Q1 2019 and held it in 1 quarter. The position peaked at $3.34M in Q1 2019. 101 funds tracked by Wall St. Rank hold CPRX as of Q2 2019.

  • Hawk Ridge Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Hawk Ridge Capital Management sold 654,859 Catalyst Pharmaceutical shares in Q2 2019, an estimated $3.34M.
  • Hawk Ridge Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2019 and held it in 1 quarter.
  • Hawk Ridge Capital Management's Catalyst Pharmaceutical position peaked at $3.34M in Q1 2019.
  • 101 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2019.

Based on Hawk Ridge Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.